NAD reviews Natrol’s BioSil
This article was originally published in The Tan Sheet
Executive Summary
Natrol provided "reasonable support" for claims it made for its liquid dietary supplement BioSil, which is indicated to promote the health of skin, hair, nails and bones in women, but the firm should modify or discontinue certain claims, according to an Oct. 21 National Advertising Division decision. NAD said Natrol, a subsidiary of India-based Plethico Pharmaceuticals, substantiated some claims with three double-blind, placebo-controlled clinical trials. However, NAD recommended the firm discontinue the claims that BioSil "reduced fine lines and wrinkles by 19 percent" and that the product is "clinically proven to give a more youthful look" in 20 weeks. Natrol said while it disagrees with NAD that some of its claims are overly broad, it will comply with the recommendations
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.